Remynd NV reported positive results from its Phase IIa trial of REM-127, a novel Alzheimer’s candidate that targets calcium homeostasis disruption caused by pathological tau. The placebo-controlled, double-blind study demonstrated reduced tau protein levels, increased dopamine, and improved cognitive function in symptomatic patients. REM-127 operates through septin filament modulation, marking a first-in-class approach in Alzheimer’s therapeutics, according to the company’s chief scientific officer.